Login Register Cart 0
Generic placeholder image

Current Clinical Pharmacology

Editor-in-Chief

ISSN (Print): 1574-8847
ISSN (Online): 2212-3938

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Preface

Medication Management Issues in Old Age: A Call for Submissions to Current Clinical Pharmacology

Author(s): Arduino A. Mangoni*, Kimberley Bryant and Elzbieta A. Jarmuzewska

Volume 14, Issue 1, 2019

Page: [2 - 4] Pages: 3

DOI: 10.2174/157488471401190301120237

« Previous Next »
[1]
Mangoni AA, Jansen PA, Jackson SH. Under-representation of older adults in pharmacokinetic and pharmacodynamic studies: a solvable problem? Expert Rev Clin Pharmacol 2013; 6: 35-9.
[2]
Jackson SH, Jansen PA, Mangoni AA. Off-label prescribing in older patients. Drugs Aging 2012; 29: 427-34.
[3]
Mangoni AA, Jackson SH. The implications of a growing evidence base for drug use in elderly patients. Part 3. Beta-adrenoceptor blockers in heart failure and thrombolytics in acute myocardial infarction. Br J Clin Pharmacol 2006; 61: 513-20.
[4]
Mangoni AA, Jackson SH. The implications of a growing evidence base for drug use in elderly patients Part 2. ACE inhibitors and angiotensin receptor blockers in heart failure and high cardiovascular risk patients. Br J Clin Pharmacol 2006; 61: 502-12.
[5]
Mangoni AA, Jackson SH. The implications of a growing evidence base for drug use in elderly patients. Part 1. Statins for primary and secondary cardiovascular prevention. Br J Clin Pharmacol 2006; 61: 494-501.
[6]
Dhesi JK, Allain TJ, Mangoni AA, Jackson SH. The implications of a growing evidence base for drug use in elderly patients. Part 4. Vitamin D and bisphosphonates for fractures and osteoporosis. Br J Clin Pharmacol 2006; 61: 521-8.
[7]
Gao L, Maidment I, Matthews FE, Robinson L, Brayne C. Medication usage change in older people (65+) in England over 20 years: findings from CFAS I and CFAS II. Age Ageing 2017; 1-6.
[8]
Sumukadas D, McMurdo ME, Mangoni AA, Guthrie B. Temporal trends in anticholinergic medication prescription in older people: repeated cross-sectional analysis of population prescribing data. Age Ageing 2014; 43: 515-21.
[9]
Hollingworth S, Duncan EL, Martin JH. Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol Drug Saf 2010; 19: 1019-24.
[10]
Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States From 1999-2012. JAMA 2015; 314: 1818-31.
[11]
Bostock CV, Soiza RL, Mangoni AA. Association between prescribing of antimuscarinic drugs and antimuscarinic adverse effects in older people. Expert Rev Clin Pharmacol 2010; 3: 441-52.
[12]
Lowry E, Woodman RJ, Soiza RL, Hilmer SN, Mangoni AA. Drug burden index, physical function, and adverse outcomes in older hospitalized patients. J Clin Pharmacol 2012; 52: 1584-91.
[13]
Lowry E, Woodman RJ, Soiza RL, Mangoni AA. Associations between the anticholinergic risk scale score and physical function: potential implications for adverse outcomes in older hospitalized patients. J Am Med Dir Assoc 2011; 12: 565-72.
[14]
Mangoni AA. Assessing the adverse effects of antimuscarinic drugs in older patients: which way forward? Expert Rev Clin Pharmacol 2011; 4: 531-3.
[15]
Mangoni AA, Crilly MA, Knights KM. Cardiovascular toxicity of nonsteroidal antiinflammatory drugs: moving beyond cyclooxygenase selectivity. Expert Rev Clin Pharmacol 2011; 4: 299-302.
[16]
Mangoni AA, Woodman RJ, Gaganis P, Gilbert AL, Knights KM. Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and allcause mortality in the Australian veteran community. Br J Clin Pharmacol 2010; 69: 689-700.
[17]
Mangoni AA, Woodman RJ, Gilbert AL, Knights KM. Use of non-steroidal antiinflammatory drugs and risk of ischemic and hemorrhagic stroke in the Australian veteran community. Pharmacoepidemiol Drug Saf 2010; 19: 490-8.
[18]
Koshoedo S, Soiza RL, Purkayastha R, Mangoni AA. Anticholinergic drugs and functional outcomes in older patients undergoing orthopaedic rehabilitation. Am J Geriatr Pharmacother 2012; 10: 251-7.
[19]
Knights KM, Mangoni AA, Miners JO. Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity. Expert Rev Clin Pharmacol 2010; 3: 769-76.
[20]
Mangoni AA, van Munster BC, Woodman RJ, de Rooij SE. Measures of anticholinergic drug exposure, serum anticholinergic activity, and all-cause postdischarge mortality in older hospitalized patients with hip fractures The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2013; (21): 785-93.
[21]
Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and metaanalysis. Br J Clin Pharmacol 2015; 80: 209-20.
[22]
Mangoni AA, Kim S, Hakendorf P, Mayner L, Woodman RJ. Heat Waves, Drugs with Anticholinergic Effects, and Outcomes in Older Hospitalized Adults. J Am Geriatr Soc 2016; 64: 1091-6.
[23]
Mangoni AA, Kholmurodova F, Mayner L, Hakendorf P, Woodman RJ. Psychotropics, Environmental Temperature, and Hospital Outcomes in Older Medical Patients. J Clin Psychopharmacol 2017; 37: 562-8.
[24]
Mangoni AA, Kholmurodova F, Mayner L, Hakendorf P, Woodman RJ. The Concomitant Use of Diuretics, Non-Steroidal Anti-Inflammatory Drugs, and Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers (Triple Whammy), Extreme Heat, and In-Hospital Acute Kidney Injury in Older Medical Patients. Advances in therapy 2017; 34: 2534-41.
[25]
Tommasi S, Elliot DJ, Hulin JA, Lewis BC, McEvoy M, Mangoni AA. Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance. Sci Rep 2017; 7: 2871.
[26]
Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004; 57: 6-14.
[27]
Mangoni AA. Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations. Drugs Aging 2005; 22: 913-41.
[28]
Reeve E, Wiese MD, Mangoni AA. Alterations in drug disposition in older adults. Expert Opin Drug Metab Toxicol 2015; 11: 491-508.
[29]
Mangoni AA, Jarmuzewska EA. The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence. Br J Clin Pharmacol 2019; 85: 20-36.
[30]
Mangoni AA, Pilotto A. New drugs and patient-centred end-points in old age: setting the wheels in motion. Expert Rev Clin Pharmacol 2016; 9: 81-9.
[31]
Mangoni AA. Temporal changes in medication use and disease management in old age: where does it all end? Age Ageing 2018; 47: 160-1.
[32]
Mangoni AA. Predicting and detecting adverse drug reactions in old age: challenges and opportunities. Expert Opin Drug Metab Toxicol 2012; 8: 527-30.
[33]
Lavan AH, Gallagher P. Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf 2016; 7: 11-22.
[34]
Galvin R, Moriarty F, Cousins G, et al. Prevalence of potentially inappropriate prescribing and prescribing omissions in older Irish adults: findings from The Irish LongituDinal Study on Ageing study (TILDA). Eur J Clin Pharmacol 2014; 70: 599-606.8.
[35]
Kuijpers MA, van Marum RJ, Egberts AC, Jansen PA, Group OS. Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol 2008; 65: 130-3.
[36]
Gutierrez-Valencia M, Izquierdo M, Cesari M, Casas-Herrero A, Inzitari M, Martinez-Velilla N. The relationship between frailty and polypharmacy in older people: A systematic review. Br J Clin Pharmacol 2018; 84: 1432-44.
[37]
Kouladjian L, Gnjidic D, Chen TF, Mangoni AA, Hilmer SN. Drug Burden Index in older adults: theoretical and practical issues. Clinical interventions in aging 2014; 9: 1503-15.
[38]
O’Connor MN, O’Sullivan D, Gallagher PF, Eustace J, Byrne S, O’Mahony D. Prevention of Hospital-Acquired Adverse Drug Reactions in Older People Using Screening Tool of Older Persons’ Prescriptions and Screening Tool to Alert to Right Treatment Criteria: A Cluster Randomized Controlled Trial. J Am Geriatr Soc 2016; 64: 1558-66.
[39]
Walsh KA, O’Riordan D, Kearney PM, Timmons S, Byrne S. Improving the appropriateness of prescribing in older patients: a systematic review and meta-analysis of pharmacists’ interventions in secondary care. Age Ageing 2016; 45: 201-9.
[40]
Clyne B, Fitzgerald C, Quinlan A, et al. Interventions to Address Potentially Inappropriate Prescribing in Community-Dwelling Older Adults: A Systematic Review of Randomized Controlled Trials. J Am Geriatr Soc 2016; 64: 1210-22.
[41]
Dalton K, O’Brien G, O’Mahony D, Byrne S. Computerised interventions designed to reduce potentially inappropriate prescribing in hospitalised older adults: a systematic review and meta-analysis. Age Ageing 2018; 47: 670-8.
[42]
Jackson SH, Mangoni AA, Batty GM. Optimization of drug prescribing. Br J Clin Pharmacol 2004; 57: 231-6.
[43]
Wilsdon TD, Hendrix I, Thynne TR, Mangoni AA. Effectiveness of Interventions to Deprescribe Inappropriate Proton Pump Inhibitors in Older Adults. Drugs Aging 2017; 34: 265-87.
[44]
Ethun CG, Bilen MA, Jani AB, Maithel SK, Ogan K, Master VA. Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology. CA Cancer J Clin 2017; 67: 362-77.
[45]
Afilalo J, Alexander KP, Mack MJ, et al. Frailty assessment in the cardiovascular care of older adults. J Am Coll Cardiol 2014; 63: 747-62.
[46]
D’Onofrio G, Sancarlo D, Addante F, et al. A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 2015; 30: 965-75.
[47]
Pilotto A, D’Onofrio G, Panza F, et al. Treatment of late-life major depressive disorder with selective serotonin reuptake inhibitors improves the multidimensional prognostic index. J Clin Psychopharmacol 2012; 32: 726-9.
[48]
Volpato S, Custureri R, Puntoni M, et al. Effects of oral amino acid supplementation on Multidimensional Prognostic Index in hospitalized older patients: a multicenter randomized, double-blind, placebo-controlled pilot study. Clinical interventions in aging 2018; 13: 633-40.

Rights & Permissions Print Cite
Article Metrics
60
10
3
3
© 2024 Bentham Science Publishers | Privacy Policy